Clinical Trial Update: FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

The FREEDOM DR trial evaluating oral treprostinil, with or without ERA or PDE-5 inhibitors, for pulmonary arterial hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Orenitram (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension | Phase 3 | Status: WITHDRAWN